FDA OKs Aurobindo’s generic Sensipar
Aurobindo has received the Food and Drug Administration’s approval for its generic Sensipar (cinacalcet hydrochloride tablets). The generic of Amgen's branded drug will be available in dosage strengths of 30 mg, 60 mg and 90 mg.
Cinacalcet hydrochloride tablets are indicated for the treatment of secondary hyperparathyroidism, in adult patients with chronic kidney disease on dialysis; hypercalcemia in adult patients with parathyroid carcinoma; and severe hypercalcemia in adult patients with primary hyperparathyroidism who are unable to undergo parathyroidectomy.
Cinacalcet hydrochloride tablets had a market value of approximately $1.45 billion for the 12 months ended May 2019, according to IQVIA.
Cinacalcet hydrochloride tablets are indicated for the treatment of secondary hyperparathyroidism, in adult patients with chronic kidney disease on dialysis; hypercalcemia in adult patients with parathyroid carcinoma; and severe hypercalcemia in adult patients with primary hyperparathyroidism who are unable to undergo parathyroidectomy.
Cinacalcet hydrochloride tablets had a market value of approximately $1.45 billion for the 12 months ended May 2019, according to IQVIA.